Drug Profile
Research programme: osteoarthritis therapeutics - Cocoon Biotech
Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Cocoon Biotech
- Class Antirheumatics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Osteoarthritis in USA (Intra-articular) (Cocoon Biotech website, October 2023)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Intra-articular, Injection)
- 07 Feb 2017 Tuft college has patent protection for silk fibroin technology and its use in USA